Tier 4 — mechanistic

Involvement of nitric oxide in learning and memory processes

Paul V, Ekambaram P
Indian Journal of Medical Research 2011 Volume 133, Issue 5, pages 471–478

Bibliography

PubMed
PMID 21623030
PubMed Central
PMC3121276
Funding
No funding statement disclosed in the published article.
Competing interests
No competing interests statement disclosed in the published article.

Study snapshot

DesignNarrative review
ModelPredominantly rodent studies (rats, mice); also chicks, goldfish, Octopus vulgaris, Aplysia, honey bees, sheep, rabbits; limited discussion of human Alzheimer's disease pathology
SampleNot applicable (review of primary animal studies with typically small experimental group sizes)
InterventionPharmacological manipulation of the nitric oxide pathway: L-arginine (NO precursor); NO donors (sodium nitroprusside, S-nitroso-N-acetylpenicillamine, molsidomine); NOS inhibitors (L-NAME, L-NA, L-NMMA, 7-nitroindazole); NMDA receptor antagonists (MK-801, AP5); phosphodiesterase inhibitor sildenafil
DurationReviewed protocols spanned acute single-dose to chronic multi-week rodent studies
EndpointsAcquisition and retention of avoidance learning tasks; spatial learning in Morris water maze and radial arm maze; object recognition memory; hippocampal long-term potentiation and long-term depression; brain nitric oxide synthase activity; brain nitrite concentrations

What the study showed, in plain terms

Your brain makes nitric oxide from the amino acid L-arginine using an enzyme called neuronal nitric oxide synthase. Because nitric oxide is a gas that diffuses freely across cell membranes, it acts as an unusual kind of neurotransmitter — one that does not sit in vesicles waiting for release, but is made on demand at the moment a nerve cell needs it. The moment usually comes when the excitatory neurotransmitter glutamate activates NMDA receptors and calcium floods into the cell.

This 2011 review pulls together roughly two decades of animal experiments testing whether nitric oxide is actually needed for learning and for storing memories. The consistent pattern: increasing brain nitric oxide (with L-arginine or with drugs that release nitric oxide) tends to improve performance on learning tasks in rats, mice, chicks, and even invertebrates like octopus and honeybees. Blocking nitric oxide synthesis with L-NAME, 7-nitroindazole, or similar inhibitors tends to impair learning and memory across the same range of species. Most of this evidence is in animals rather than humans.

The review also examines conditions in which brain nitric oxide is thought to be low — ageing, diabetes, chronic stress, epilepsy, and Alzheimer's disease. In each case, animal models show cognitive deficits alongside reduced nitric oxide activity. In rodent models of ageing, L-arginine and nitric oxide donors have partially reversed those deficits. The authors argue this preclinical pattern supports investigating L-arginine and nitric oxide donors for age-related cognitive decline in humans, though direct clinical trial evidence is not the focus of this review.

Key findings

  • Long-term potentiation and long-term depression in the hippocampus — considered the primary cellular substrates of learning and memory — require nitric oxide acting as a retrograde messenger.
  • Learning tasks in rats are accompanied by measurable elevations of hippocampal nitrite and by roughly 45% increases in NOS activity immediately after acquisition of avoidance tasks.
  • Inhibitors of nitric oxide synthase (L-NAME, L-NA, L-NMMA, 7-nitroindazole) impair acquisition and retention across avoidance, maze, olfactory, and object-recognition tasks in rats, chicks, mice, goldfish, octopus, Aplysia, and honeybees.
  • L-arginine, sodium nitroprusside, S-nitroso-N-acetylpenicillamine, and molsidomine facilitate learning and memory across similar tasks in rodents.
  • The effect is dose-dependent and biphasic: very high doses of L-arginine or NO donors impair memory, consistent with a neurotoxic accumulation of peroxynitrite at supraphysiological nitric oxide concentrations.
  • Ageing in rats is associated with a 30–50% decrease in nitric oxide production and with slower learning; ageing-induced memory impairment was reversed by L-arginine and sodium nitroprusside in reviewed studies.
  • Beta-amyloid, the toxic protein deposited in Alzheimer's disease, is reported to inhibit hippocampal nitric oxide synthesis and NMDA-dependent long-term potentiation, providing a proposed mechanistic link between defective nitric oxide signalling and Alzheimer-type dementia.
  • Nitric oxide donors and precursors partially reversed learning and memory impairment induced by antiepileptic drugs (phenobarbitone), morphine, and diabetes in rodent models.

What this study can and cannot tell us

This is a narrative review of predominantly animal-model evidence. The overwhelming majority of studies cited use rodents; a smaller subset uses chicks, fish, or invertebrates. There is essentially no direct human clinical trial data on L-arginine or nitric oxide donor supplementation for cognition included in this review. The authors' recommendations regarding L-arginine or nitric oxide donors for Alzheimer's disease rest on animal mechanistic data plus a small number of external reports rather than on adequately powered human trials.

No formal search strategy, inclusion criteria, or risk-of-bias assessment is described. Study selection appears purposive. The review does not distinguish clearly between effects on encoding, consolidation, and retrieval; it also does not systematically address dose-response, timing of intervention relative to task, or the ceiling above which nitric oxide becomes neurotoxic.

Extrapolation from rodent brain physiology to human cognitive function is non-trivial. Even where a peripheral supplement such as oral L-arginine raises plasma L-arginine, the extent to which it modulates central nervous system nitric oxide synthesis in humans is uncertain and not addressed empirically here. No funding statement or competing interests declaration is disclosed in the published article, which is unusual for a review of this scope.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified